The Real Anthony Fauci Book › Citations Chapter 1 - Ivermectin This is a listing of all citations in this chapter. 1 The Nobel Prize in Physiology or Medicine 2015, The Nobel Prize Press Release (Oct. 5, 2015). 2 World Health Organization, “Executive summary: the selection and use of essential medicines 2021: report of the 23rd WHO Expert Committee on the selection and use of essential medicines,” WHO (Sept. 30, 2021). 3 World Health Organization, “World Health Organization Model List of Essential Medicines—22nd List,” WHO (2021). 4 Andy Crump and Satoshi Ōmura, “Ivermectin, ‘Wonder drug’ from Japan: the human use perspective,” Proceedings of the Japan Academy, Series B (Feb. 10, 2011). 5 Fatemeh Heidary and Reza Gharebaghi, “Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen,” The Journal of Antibiotics (Jun. 12, 2020). 6 Monash University, “Lab experiments show anti-parasitic drug, Ivermectin, eliminates SARS-CoV-2 in cells in 48 hours.” Monash Biomedicine Discovery Institute (April 3, 2020). 7 Monash University, “Lab experiments show anti-parasitic drug, Ivermectin, eliminates SARS-CoV-2 in cells in 48 hours.” Monash Biomedicine Discovery Institute (Apr. 3, 2020). 8 Juan Chamie-Quintero et al., “Ivermectin for COVID in Peru: 14-fold reduction in nationwide excess deaths, p<0.002 for effect by state, then 13-fold increase after ivermectin use restricted,” OSF Preprints (Mar. 8, 2021). 9 Hector Carvallo, et al., “Study of the Efficacy and Safety of Topical Ivermectin + IotaCarrageenan in the Prophylaxis against COVID-19 in Health Personnel,” Journal of Biomedical Research and Clinical Investigation 2 no. 1 (Nov. 17, 2020):1007. 10 Alam et al., “Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka—An Observational Study,” European Journal of Medical & Health Sciences 2 No. 6 (Published Dec. 15, 2020). 11 AD Santin, et al., “Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge,” New Microbes New Infect 3,43 (Aug. 3, 2021):100924, doi: 10.1016/j.nmni.2021.100924. 12 Statement to U.S. Committee on Homeland Security and Governmental Affairs: “THE ICON STUDY: Dr. Jean-Jacques Rajter Reviews Ivermectin: Early Outpatient Treatment: An Essential Part of the COVID-19 Solution, Part II.,” Hope Pressworks (Jan. 18, 2021). 13 Alam et al., “Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka—An Observational Study,” Alam et al., European Journal of Medical & Health Sciences, 2 No. 6 (Published Dec. 15, 2020). 14 Peter A. McCullough et al., “Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19).” Reviews in Cardiovascular Medicine 21 no. 4 (Dec. 2020): 517-530. 15 Ivermectineforcovid.com, “A Letter to NIH and Dr. Anthony Fauci. Is Anybody Home?” Ivermectin for COVID (Mar. 4, 2021). 16 C. Bernigaud et al., “Bénéfice de l’ivermectine: de la gale à la COVID-19, un exemple de sérendipité,” Annales de Dermatologie et de Vénéréologie 147 no. 12 (December, 2020):A194. 17 C. Bernigaud et al., “Ivermectin benefit: from scabies to COVID-19, an example of serendipity,” Annals of Dermatology and Venereology (Dec. 2020). 18 Choudhury, Abhigyan et al.,“Exploring the Binding Efficacy of Ivermectin against the Key Proteins of SARS-CoV-2 Pathogenesis: An in Silico Approach,” Future Virology (Mar. 25, 2021). 19 Peter A. McCullough et al., “Early Ambulatory Multidrug Therapy Reduces Hospitalization and Death in High-Risk Patients with SARS-CoV-2 (COVID-19),” 6 No. 03 (Mar. 2021): 219–221. 20 FLCCC Press Release, “FLCCC Alliance Invited to the National Institutes of Health (NIH) COVID-19 Treatment Guidelines Panel to Present Latest Data on Ivermectin,” Front Line COVID-19 Critical Care Alliance (FLCCC) (Jan. 7, 2021). 21 Dr. Andrew Hill, “Covid-19: WHO-sponsored preliminary review indicates Ivermectin effectiveness,” Swiss Policy Research (Dec. 31, 2020). 22 Carlos Chaccour, “The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial,” EClinical Medicine Published by the Lancet (Jan. 19, 2021). 23 Pierre Kory, et al., “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19,” Front Line COVID-10 Critical Care Alliance (Jan. 16, 2021). 24 FLCCC Press release, “Dr. Pierre Kory, president of the FLCCC Alliance testifies before Senate Committee on Homeland Security and Governmental Affairs looking into early outpatient COVID-19 treatment,” Front Line COVID-19 Critical Care Alliance (FLCCC) (Dec. 8, 2020). 25 Pierre Kory et al., “Clinical and Scientific Rationale for the “MATH+” Hospital Treatment Protocol for COVID-19,” Journal of Intensive Care Medicine (Dec. 15, 2020). 26 FLCCC, “One Page Summary of the Clinical Trials Evidence for Ivermectin in COVID-19,” Front Line COVID-19 Critical Care Alliance (FLCCC) (Jan. 11, 2021). 27 FLCCC, “Testimony by Dr. Pierre Kory to the U.S. Senate Committee on Homeland Security and Governmental Affairs (2020).” Front Line COVID-19 Critical Care Alliance (FLCCC). 28 FLCCC, “FLCCC Alliance Invited to the National Institutes of Health (NIH) COVID-19 Treatment Guidelines Panel to Present Latest Data on Ivermectin,” Press Release, Front Line COVID-19 Critical Care Alliance (FLCCC), (Jan. 7, 2021). 29 Donato Paolo Mancini, “Cheap antiparasitic could cut chance of Covid-19 deaths by up to 75%,” The Financial Times (Jan. 19, 2021). 30 “NIH Updates its Position on Ivermectin,” COVEXIT: COVID-19 News & Policy Analysis (Jan. 14, 2021). Page 1 of 41234»